GLP-1 Results Timeline: What to Expect Month by Month
A realistic month-by-month picture of GLP-1 weight loss — when appetite changes start, when the scale moves, plateaus, and what maintenance looks like.
6 min read · Last reviewed 2026-09-01 by the TopGLP1 Editorial Team
Educational, not medical advice. This page explains GLP-1 medications in general terms. Only a licensed clinician who knows your history can decide what's right for you.
Key takeaways
- Appetite often drops in week 1–2, before the scale moves much.
- Most trial weight loss accrues over the first 6–9 months.
- Plateaus are normal and often line up with dose steps.
- Stopping usually leads to regain — GLP-1 is a long-term therapy.
Weeks 1–4: appetite before the scale
On the starter dose, the point isn't weight loss — it's tolerance. Still, many people notice reduced hunger and less “food noise” within the first week or two. Early scale movement is often modest and partly water. Side effects, if they come, are usually at their most noticeable here.
Months 2–4: the steady descent
As you step up to therapeutic doses, weight loss typically becomes steadier — often in the range of a few pounds a month, though it varies widely. This is where habits set now (protein, resistance training, sleep) pay off later by protecting muscle and making the loss sustainable.
Months 5–9: most of the results
In the major trials, the bulk of average weight loss accumulated across roughly the first six to nine months before curves began to flatten. For semaglutide that averaged around 15% of body weight; for tirzepatide, up to ~20%+ at higher doses. Your own result depends on dose, consistency, starting point and biology.
Plateaus are normal
Weight loss is rarely linear. Plateaus of a few weeks are expected and often coincide with being between dose steps or with your body reaching a new set point. A genuine, sustained plateau is a reason to talk to your clinician about dose, nutrition or activity — not necessarily a sign the drug has “stopped working.”
Maintenance and stopping
GLP-1 medications treat the biology of appetite, and that biology returns when you stop. Studies consistently show most people regain a large share of lost weight within a year of discontinuation. For that reason these drugs are generally used as long-term therapy, with dose sometimes adjusted for maintenance rather than stopped outright. Any plan to come off should be a deliberate conversation with your prescriber.
Sources & references
Clinical figures on this page trace to peer-reviewed trials and official regulators. We link the primary record so you can verify it yourself.
- 1.Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002.Clinical trialNew England Journal of Medicine
- 2.Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205–216.Clinical trialNew England Journal of Medicine
- 3.Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025.Clinical trialNew England Journal of Medicine